Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 201–300 of 856
Decoding metabolic signatures in Alzheimer’s disease: a mitochondrial perspective
Bano, D., Ehninger, D., & Bagetta, G. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01732-3 · Cited by 46
“…for a link between mitochondria and AD, an increasing number of studies have reported changes in brain glucose and oxygen metabolism as well as mitochondrial respiratory defects and/or morphological abnormalities in tissues exhibiting typical AD-related neuropathological changes [26, 28, 44].”
BackgroundMitochondrial Dysfunction in Alzheimer’s Disease and Progress in Mitochondria-Targeted Therapeutics
Flannery, P. J., & Trushina, E. V. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00179-0 · Cited by 43
Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
Poor, S. R., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Olloquequi, J., Camins, A., & Javan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090890 · Cited by 44
Yin, Z., Geng, X., Zhang, Z., Wang, Y., & Gao, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.746711 · Cited by 40
“Mounting evidence indicates neuronal oxidative stress induced by β-amyloid (Aβ) is considered to be a critical pathological event in AD, although the etiology of AD has not been fully elucidated (Lin and Beal, 2006; Borger et al., 2011; Swerdlow, 2018).”
BackgroundKodavati, M. M., Wang, H., Guo, W., Mitra, J., Hegde, P. M., Provasek, V. E., Rao, V. H. M., Vedula, I., Zhang, A., MITRA, S. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45978-6 · Cited by 41
Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
Kolaj, I., Imindu Liyanage, S., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39
““The mitochondrial cascade hypothesis”, therefore suggests that mitochondrial dysfunction may play a central role in initiating key AD pathologies, including Aβ production, tau hyperphosphorylation, synaptic loss and neurodegeneration (Onyango et al., 2016; Swerdlow, 2018; Swerdlow and Khan, 2004).”
Fišar, Z., Jirák, R., Zvěřová, M., Setnička, V., Habartová, L., Hroudová, J., Vaníčková, Z., & Raboch, J. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.003 · Cited by 39
Mitochondrial-Targeted Antioxidants Attenuate TGF-β2 Signaling in Human Trabecular Meshwork Cells
Rao, V. R., Lautz, J. D., Kaja, S., Foecking, E. M., Lukacs, E., & Stubbs, E. B. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-27542 · Cited by 40
Blood Neuroexosomal Mitochondrial Proteins Predict Alzheimer Disease in Diabetes
Chi, H., Yao, R., Sun, C., Leng, B., Shen, T., Wang, T., Zhang, S., Li, M., Yang, Y., Sun, H., et al. (2022) · Diabetes · doi:10.2337/db21-0969 · Cited by 42
Carbone, M. G., Pagni, G., Tagliarini, C., Imbimbo, B. P., & Pomara, N. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101420 · Cited by 42
CNS Redox Homeostasis and Dysfunction in Neurodegenerative Diseases
Goldsteins, G., Hakosalo, V., Jaronen, M., Keuters, M. H., Lehtonen, Š., & Koıstınaho, J. (2022) · Antioxidants · doi:10.3390/antiox11020405 · Cited by 44
Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases
Poppell, M., Hammel, G., & Ren, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065925 · Cited by 41
The multiple roles of chronic stress and glucocorticoids in Alzheimer's disease pathogenesis
Burke, M. R., Sotiropoulos, I., & Waites, C. L. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.015 · Cited by 46
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 42
“In fact, mitochondrial dysfunction has been frequently reported in AD [159], and, therefore, it has given support to another theory, the so-called mitochondrial cascade hypothesis [160–162].”
Richard, P., Manière, X., Kozlowski, L., Guillorit, H., Garnier, P., Danchin, A., & McKnight, N. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253216 · Cited by 43
“Aberrations in mitochondrial function can contribute to the molecular pathogenesis of both PD [57] and AD [58].”
BackgroundZhu, L., Lu, F., Zhang, X., Liu, S., & Mu, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877098 · Cited by 48
“Mitochondrial damage, such as membrane potential loss, cristae disorder, and imbalanced fusion–fission status, was observed in AD models (Swerdlow, 2018).”
BackgroundmtDNA Maintenance and Alterations in the Pathogenesis of Neurodegenerative Diseases
Shang, D., Huang, M., Wang, B., Yan, X., Wu, Z., & Zhang, X. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220810114644 · Cited by 51
“The mitochondrial cascade hypothesis suggests that the accumulation of mtDNA modifications and mutations in brain somatic cells with age determines the disease phenotype [126, 205].”
Peng, S., Wang, Y., Sun, Z., Zhao, L., Huang, Y., Fu, X., Luo, R., Xue, J., Yang, S., Ling, L., et al. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113214 · Cited by 40
Li, X., Wu, Z., Si, X., Li, J., Wu, G., & Wang, M. (2025) · European journal of medical research · doi:10.1186/s40001-025-02699-w · Cited by 53
“Both these processes, in turn, cause further mitochondrial damage [15, 16].”
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 46
Mind the Gap: Mitochondria and the Endoplasmic Reticulum in Neurodegenerative Diseases
Leal, N. S., & Martins, L. M. (2021) · Biomedicines · doi:10.3390/biomedicines9020227 · Cited by 42
Pupyshev, A. B., Беличенко, В. М., Tenditnik, M. V., Bashirzade, A. A., Dubrovina, N. I., Ovsyukova, M. V., Akopyan, A. A., Fedoseeva, L. A., Короленко, Т. А., Amstislavskaya, T. G., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173406 · Cited by 40
Dissecting the brain with spatially resolved multi-omics
Fangma, Y., Liu, M., Liao, J., Chen, Z., & Zheng, Y. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.04.003 · Cited by 41
“This fi nding supports the widely held notion that dysfunctional mitochondria contribute to AD pathology [74] and further identi fi es BOK may be a potential therapeutic target for AD.”
BackgroundValentin‐Escalera, J., Leclerc, M., & Calon, F. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230118 · Cited by 42
Denver, P., D’Adamo, H., Hu, S., Zuo, X., Zhu, C., Okuma, C., Kim, P., Castro, D., Jones, M. R., Leal, C. D. R., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01269 · Cited by 44
Cory‐Slechta, D. A., Sobolewski, M., & Oberdörster, G. (2020) · Atmosphere · doi:10.3390/atmos11101098 · Cited by 41
Liu, X., Wang, K., Wei, X., Xie, T., Lv, B., Zhou, Q., & Wang, X. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03227-y · Cited by 41
Alldred, M. J., Penikalapati, S. C., Lee, S. H., Heguy, A., Roussos, P., & Ginsberg, S. D. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02453-3 · Cited by 35
Li, J., Wang, T., Hou, X., Li, Y., Zhang, J., Bai, W., Qian, H., & Sun, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02750-8 · Cited by 44
“However, recent findings indicate that mitochondrial dysfunction represents an early stage in the development of AD and could potentially contribute to or exacerbate its progression [55].”
Alzheimer's disease mechanisms in peripheral cells: Promises and challenges
Trushina, E. V. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.008 · Cited by 37
“Indeed, the “mitochondrial cascade hypothesis” proposes that an individual’s genetic predisposition, environmental exposure, and lifestyle could affect mitochondrial function and mediate, drive, and/or contribute to a variety of AD pathologies [31].”
BackgroundRole of PITRM1 in Mitochondrial Dysfunction and Neurodegeneration
Brunetti, D., Catania, A., Viscomi, C. F., Deleidi, M., Bindoff, L. A., Ghezzi, D., & Zeviani, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070833 · Cited by 42
“In AD, for example, the “mitochondrial cascade” hypothesis proposes that organellar dysfunction is the primary event in AD pathology [17].”
BackgroundLu, C., Tan, C., Ouyang, H., Chen, Z., Yan, Z., & Zhang, M. (2022) · Aging and Disease · doi:10.14336/ad.2022.01302 · Cited by 38
“Mitochondrial damage in ferroptosis has also been related to neurodegenerative diseases, such as Alzheimer's Disease, Parkinson's disease, and amyotrophic lateral sclerosis [151-154].”
BackgroundAPOE expression and secretion are modulated by mitochondrial dysfunction
Wynne, M. E., Ogunbona, O., Lane, A. R., Gokhale, A., Zlatic, S. A., Xu, C., Wen, Z., Duong, D. M., Rayaprolu, S., Ivanova, A., et al. (2023) · eLife · doi:10.7554/elife.85779 · Cited by 35
Singh, N., Nandy, S. K., Jyoti, A., Saxena, J., Sharma, A., Siddiqui, A. J., & Sharma, L. K. (2024) · Brain Sciences · doi:10.3390/brainsci14060554 · Cited by 39
Mitonuclear interactions influence Alzheimer's disease risk
Andrews, S. J., Fulton‐Howard, B., Patterson, C., McFall, G. P., Gross, A. L., Michaelis, E. K., Goate, A., Swerdlow, R. H., Pa, J., & Initiative, F. T. A. D. N. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.007 · Cited by 40
Self-citationCallizot, N., Campanari, M., Rouvière, L., Jacquemot, G., Henriques, A. T., Garayev, E., & Poindron, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681532 · Cited by 39
“Other relevant factors, including cholinergic dysfunction, neuroinflammation, oxidative stress, mitochondria dysfunctions, disturbance of neuronal plasticity, age-related loss of sex hormones are important and contribute to the understanding of AD pathology (Richter et al., 2014; Heneka et al., 2015; Jang and Chung, 2…”
BackgroundEarly Onset of Sex-Dependent Mitochondrial Deficits in the Cortex of 3xTg Alzheimer’s Mice
Djordjevic, J., Chowdhury, S. R., Snow, W. M., Pérez, C. I., Cadonic, C., Fernyhough, P., & Albensi, B. C. (2020) · Cells · doi:10.3390/cells9061541 · Cited by 37
“Mitochondrial anomalies occur early in disease progression [4], with individuals displaying early metabolic changes (impaired glucose metabolism, mitochondrial dysfunction, and altered energy homeostasis) prior to the emergence of any histopathological or clinical abnormalities.”
BackgroundAilioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 44
Neuro-protective effects of aloperine in an Alzheimer’s disease cellular model
Zhao, J., Zhang, G., Li, M., Luo, Q., Leng, Y., & Liu, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.008 · Cited by 37
MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease
Pohland, M., Pellowska, M., Asseburg, H., Hagl, S., Reutzel, M., Joppe, A., Berressem, D., Eckert, S. H., Wurglics, M., Schubert‐Zsilavecz, M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0342-6 · Cited by 33
“This concept suggests that mitochondria at least mediate or possibly even initiate pathologic molecular cascades in AD [30].”
BackgroundTakeda, K., Uda, A., Mitsubori, M., Nagashima, S., Iwasaki, H., Ito, N., Shiiba, I., Ishido, S., Matsuoka, M., Inatome, R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01720-2 · Cited by 32
Is osteoarthritis a mitochondrial disease? What is the evidence
Fernández-Moreno, M., Rego-Pérez, I., & Blanco, F. J. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000855 · Cited by 34
Atlante, A., & Valenti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115951 · Cited by 35
“Therefore, pathogenic mitochondrial alterations in AD are likely to be a consequence of a cumulative effect in which mitochondrial dysfunction and A β accumulation influence each other [94,155].”
BackgroundResultJia, H., Zhang, Y., & Huang, Y. H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.033 · Cited by 33
Brooks, L. R. K., & Mias, G. I. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00392 · Cited by 32
“For instance, mitochondrial dysfunction has been previously associated with AD and characterized to cause A β deposition, higher production of reactive oxygen species and lowered ATP production (Swerdlow, 2018; Moreira et al., 2010; Onyango et al., 2016).”
BackgroundMolecular targets and therapeutic interventions for iron induced neurodegeneration
Bagwe‐Parab, S., & Kaur, G. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.12.011 · Cited by 34
CGA restrains the apoptosis of Aβ25-35-induced hippocampal neurons
Shi, M., Sun, F., Wang, Y., Kang, J., Zhang, S., & Li, H. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1702547 · Cited by 34
Jové, M., Mota‐Martorell, N., Torres, P., Ayala, V., Portero‐Otín, M., Ferrer, I., & Pamplona, R. (2021) · Life · doi:10.3390/life11050388 · Cited by 33
“Therefore, accumulated data suggest that mitochondrial-bioenergetic dysfunction represents a fundamental AD event [128,139,140].”
BackgroundAmyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
Morfino, P., Aimo, A., Panichella, G., Rapezzi, C., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10237-7 · Cited by 38
H2S-based fluorescent imaging for pathophysiological processes
Jia, T.-T., Zhang, Y., Hou, J., Niu, H., & Wang, S. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1126309 · Cited by 33
“Mitochondria have been used as therapeutic targets for AD (Reddy, 2009;Wang and Chen, 2016; Swerdlow, 2018).”
MethodBiomarkers associated with the pathogenesis of Alzheimer’s disease
Wang, H., Sun, M., Li, W., Liu, X., Zhu, M., & Qin, H. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1279046 · Cited by 41
“The function of mitochondria changes with age, and it may affect the pathological changes related to AD (Swerdlow and Khan, 2004; Swerdlow et al., 2018).”
BackgroundMitochondrial Aging in the CNS: Unravelling Implications for Neurological Health and Disease
Steffan, D., Pezzini, C., Esposito, M., & Franco‐Romero, A. (2025) · Biomolecules · doi:10.3390/biom15091252 · Cited by 40
“Among these, mitochondrial impairment has been proposed as an early metabolic alteration and a major feature of the disease, playing a pivotal role as both a driver and predisposing factor in the onset and/or progression of AD (Figure 2) [158].”
The role of cell type-specific mitochondrial dysfunction in the pathogenesis of Alzheimer's disease
Kim, D., & Mook‐Jung, I. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.12.282 · Cited by 32
“involved in the pathogenesis of AD (11, 12).”
BackgroundDiscontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Mitochondrial DNA Manipulations Affect Tau Oligomerization
Weidling, I. W., Wilkins, H., Koppel, S. J., Hutfles, L. J., Wang, X., Kalani, A., Menta, B. W., Ryan, B. J., Ortiz, J. P., Gamblin, T. C., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200286 · Cited by 34
“Multiple studies concluded mtDNA does contribute, but the responsible mtDNA signature remains unclear [2, 14, 63, 64].”
Self-citationPugazhendhi, A., Suganthy, N., Chau, T. P., Sharma, A., Unpaprom, Y., Ramaraj, R., Karuppusamy, I., & Brindhadevi, K. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.08.025 · Cited by 29
Sayeed, N., & Sugaya, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272511 · Cited by 37
“Several pieces of evidence depict that mitochondrial dysfunction either precedes the disease pathology or exacerbates the pathogenesis [5, 6].”
BackgroundThe Journey of Mitochondrial Protein Import and the Roadmap to Follow
Haastrup, M. O., Vikramdeo, K. S., Singh, S., Singh, A. P., & Dasgupta, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032479 · Cited by 38
“mitochondrial dysfunction plays a key role in AD pathogenesis, as proper mitochondrial functioning is essential for neuronal health [97,98].”
Maszka, P., Kwaśniak-Butowska, M., Cysewski, D., Sławek, J. W., Smolenski, R. T., & Tomczyk, M. (2023) · Metabolites · doi:10.3390/metabo13030369 · Cited by 35
“Interestingly, both Aβ and AβPP have been observed to colocalize with mitochondria through binding to alcohol dehydrogenase [73].”
BackgroundThe potential roles of ATF family in the treatment of Alzheimer's disease
Yang, T., Zhang, Y., Chen, L., Thomas, E. R., Yu, W., Cheng, B., & Li, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114544 · Cited by 36
Chiang, M., Nicol, C. J. B., Cheng, Y., Yen, C., Lin, C., Chen, S., & Huang, R. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.03.040 · Cited by 32
Elder, M. K., Erdjument‐Bromage, H., Oliveira, M. M., Mamcarz, M., Neubert, T. A., & Klann, E. (2021) · Communications Biology · doi:10.1038/s42003-021-02324-6 · Cited by 40
Beta-Amyloid Instigates Dysfunction of Mitochondria in Cardiac Cells
Jang, S., Chapa‐Dubocq, X. R., Parodi‐Rullán, R. M., Fossati, S., & Javadov, S. A. (2022) · Cells · doi:10.3390/cells11030373 · Cited by 34
Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals
Stoccoro, A., Baldacci, F., Ceravolo, R., Giampietri, L., Tognoni, G., Siciliano, G., Migliore, L., & Coppedè, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105393 · Cited by 36
“This hypothesis is based on evidence from several studies performed in the brain and peripheral tissues from animal models of AD and human patients, which show altered mitochondrial metabolism even before detectable changes in Aβ [15].”
MethodSingh, A., Singh, K., Kaur, J., Kaur, R., Sharma, A., Kaur, J., Kaur, U., Chadha, R., & Bedi, P. M. S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00393 · Cited by 30
Yang, X., Zhou, P., Zhao, Z., Li, J., Fan, Z., Li, X., Cui, Z., & Fu, A. (2023) · Antioxidants · doi:10.3390/antiox12112006 · Cited by 33
de Vries, L. E., Jongejan, A., Fortes, J. M., Balesar, R. A., Rozemüller, A. J. M., Moerland, P. D., Huitinga, I., Swaab, D. F., & Verhaagen, J. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01760-9 · Cited by 32
Tong, T., Zhu, C., Farrell, J. J., Khurshid, Z., Initiative, A. D. N., Martin, E. R., Pericak‐Vance, M. A., Wang, L.-S., Bush, W. S., Schellenberg, G. D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01601-w · Cited by 36
“Mitochondrial dysfunction has also been extensively studied and may become a novel therapeu - tic target for AD [13, 14].”
Mitochondrial-based therapies for neurodegenerative diseases: a review of the current literature
Wadan, A. S., Shaaban, A., El-Sadek, M. Z., Mostafa, S. A., Moshref, A. S., El‐Hussein, A., Ellakwa, D. E., & Mehanny, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04014-0 · Cited by 47
“2) (Swerdlow 2018; Reddy and Oliver 2019; Wang et al. 2008).”
Bioenergetic failure and oxidative stress: mitochondrial contributions to Alzheimer’s disease
Wasim, R. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01916-6 · Cited by 33
“Many studies have shown that AD patients' brains have widespread mitochondrial abnormalities (Swerdlow.”
Bao, Y. W., Hu, C., Wang, B., Liu, X., Wu, Q., Xu, D., Shi, Z., & Sun, C. (2025) · Biology · doi:10.3390/biology14091140 · Cited by 42
“Neurodegenerative diseases are characterized by progressive neuronal dysfunction and structural loss, leading to cognitive and motor impairments [80].”
Post-Translational Modifications of BACE1 in Alzheimer's Disease
Wen, W., Li, P., Liu, P., Xu, S., Wang, F., & Huang, J. H. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210121163224 · Cited by 36
Skok, M. V. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106138 · Cited by 29
Nikkar, R., Esmaeili‐bandboni, A., Badrikoohi, M., & Babaei, P. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00940-7 · Cited by 30
“2017) releasing TNF-α (Hirsch and Hunot 2009), disturbing neural metabolism (Kapogiannis and Mattson 2011) and mitochondrial functions (Swerdlow 2018; Wang et al.”
BackgroundTargeting mitochondria in the regulation of neurodegenerative diseases: A comprehensive review
Maurya, S. K., Gupta, S., Bakshi, A., Kaur, H., Jain, A., Senapati, S., & Baghel, M. S. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25110 · Cited by 31
“A recent study reported the accumulation of Aβ as a triggering factor for mitochondrial dysfunction in AD (Swerdlow, 2018). mtDNA is vulnerable to oxidative damage due to lack of histones, continuous exposure to ROS, and minimum DNA repair mechanism (Verri et al., 2012).”
BackgroundRajkumar, M., Vimala, K., Tamiliniyan, D. D., Thangaraj, R., Ramakrishnan, J., Kumaradhas, P., & Kannan, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.010 · Cited by 30
Wang, Y., Wang, K., Yan, J., Zhou, Q., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213886 · Cited by 39
Jett, S., Dyke, J. P., Andy, C., Schelbaum, E., Jang, G., Boneu, C., Pahlajani, S. S., Diaz, I., Brinton, R. D., & Mosconi, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-26573-5 · Cited by 33
Ertaş, A., Yiğitkan, S., & Orhan, İ. E. (2023) · Pharmaceuticals · doi:10.3390/ph16020171 · Cited by 35
The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy
Wang, T., & Jia, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512025 · Cited by 34
“However, the exact cause of AD has not been fully elucidated, although many hypotheses on its etiology and pathogenesis have been put forward, including the Aβ cascade hypothesis [4], the misfolded tau protein hypothesis [5], the cholinergic hypothesis [6–9], oxidative stress [10], calcium dyshomeostasis [11,12], neur…”
BackgroundGuha, S., Mathew, N. D., Konkwo, C., Ostrovsky, J., Kwon, Y. J., Polyák, E., Seiler, C., Bennett, M. J., Xiao, R., Zhang, Z., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab059 · Cited by 30
“…RC dysfunction may also secondarily result from a wide array of other genetic conditions, medicationsorenvironmentalexposures,andisrecognizedtobe a common pathophysiologic occurrence in metabolic syndrome, aging and neurodegenerative disorders such as Alzheimer and Parkinson’s diseases (3–7).”
Jett, S., Boneu, C., Zarate, C., Carlton, C., Kodancha, V., Nerattini, M., Battista, M., Pahlajani, S. S., Williams, S., Dyke, J. P., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1183228 · Cited by 32
“and brain glucose hypometabolism are consistently observed in AD (Lin and Beal, 2006; Gibson and Shi, 2010; Swerdlow, 2018; Chételat et al., 2020; Bao et al., 2021).”
BackgroundSalcedo, C., Garcia, V. P., García‐Adán, B., Ameen, A. O., Gegelashvili, G., Waagepetersen, H. S., Freude, K., & Aldana, B. I. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16014 · Cited by 30
“In addition, mounting evidence indicates a link between mitochondria dysfunction, oxidative stress, and AD pathogenesis (Cenini & Voos, 2019; Gibson et al., 2010 ; Swerdlow, 2018 ; Wang et al., 2020 ).”
BackgroundNeurodegenerative disorders, metabolic icebergs, and mitohormesis
Phillips, M. C. L., & Picard, M. A. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00435-8 · Cited by 33
“Human neuroimaging and post-mortem studies show that impaired mitochondrial biology occurs early in the pathogenesis of AD [79].”
BackgroundNaik, R. A., Mir, M. N., Malik, I. A., Bhardwaj, R., Alshabrmi, F. M., Mahmoud, M. A., Alhomrani, M., Alamri, A. S., Alsanie, W. F., Hjazi, A. M., et al. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25551 · Cited by 35
Mani, S., Wasnik, S., Shandilya, C., Srivastava, V., Khan, S., & Singh, K. K. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1615764 · Cited by 35
“Furthermore, this aggregation modi fi es mitochondrial genetic makeup, further impairing their capacity for ef fi cient operation (Swerdlow, 2018).”
Genetic heterogeneity of Alzheimer’s disease in subjects with and without hypertension
Nazarian, A., Arbeev, K. G., Yashkin, A. P., & Kulminski, A. M. (2019) · GeroScience · doi:10.1007/s11357-019-00071-5 · Cited by 29
“For instance, mitochondrial dysfunction has been reported as an important pathologic finding in AD patients which may both result from and promote Aβ deposition (Swerdlow 2017).”
BackgroundUric acid and late-onset Alzheimer’s disease: results from the ReGAl 2.0 project
ReGAl 2.0 Study Group:, Boccardi, V., Carino, S., Marinelli, E., Lapenna, M., Caironi, G., Bianco, A. R., Cecchetti, R., Ruggiero, C., & Mecocci, P. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01541-z · Cited by 32
Multifunctional nano-enabled delivery systems in Alzheimer's disease management
Qian, C., Yuan, C., Li, C., Liu, H., & Wang, X. (2020) · Biomaterials Science · doi:10.1039/d0bm00756k · Cited by 28
Terada, T., Therriault, J., Kang, M. S., Savard, M., Pascoal, T. A., Lussier, F. Z., Tissot, C., Wang, Y., Benedet, A. L., Poltronetti, N. M., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15246 · Cited by 31
“Mitochondrial dysfunction is increasingly being recognized as playing a pivotal role in the pathogenesis of AD [5].”
BackgroundInfluentialROCK2 inhibition: A futuristic approach for the management of Alzheimer’s disease
Mani, S., Jindal, D., Chopra, H., Jha, S. K., Singh, S. K., Ashraf, G. M., Kamal, M., Iqbal, D., Chellappan, D. K., Dey, A., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104871 · Cited by 29
Oxidative Stress in Brain in Amnestic Mild Cognitive Impairment
Butterfield, D. A. (2023) · Antioxidants · doi:10.3390/antiox12020462 · Cited by 32
“It is well known that mitochondrial functions are deficient in AD [130,131] and MCI [86,132], and our studies showing specific mitochondrial proteins are oxidatively modified contribute to the understanding of why brain mitochondrial functions are diminished in these disorders compared to age-matched control brains.”
BackgroundBoeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01206-2 · Cited by 39
“40 impair critical mitochondrial functions [52].”
El Massry, M., Alaeddine, L. M., Ali, L., Saad, C., & Eid, A. A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908114902 · Cited by 27
Pakpian, N., Phopin, K., Kitidee, K., Govitrapong, P., & Wongchitrat, P. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201006162538 · Cited by 30
Biological and disease hallmarks of Alzheimer’s disease defined by Alzheimer’s disease genes
Murakami, S., & Lacayo, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.996030 · Cited by 30
“It may be consistent with mitochondrial deletions known to occur during aging, which may cause mitochondrial deficits (Jang et al., 2018; Swerdlow, 2018).”
BackgroundObesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline
Anderson, T., Sharma, S. K., Kelberman, M. A., Ware, C. B., Guo, N., Qin, Z. S., Weinshenker, D., & Parent, M. B. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15900 · Cited by 26
“Obesity and AD share common brain metabolic signatures; both decrease hippocampal activation of the metabolic regulator AMP-activated protein kinase (AMPK) and damage mitochondria by pro - ducing excess reactive oxygen species (ROS) (Cavaliere et al., 2018; Qiu & Schlegel, 2018 ; Swerdlow, 2018 ).”
BackgroundZou, D., Huang, X., Lan, Y., Pan, M., Xie, J., Huang, Q., Zeng, J., Zou, C., Pei, Z., Zou, C., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107098 · Cited by 30
Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 30
Panes-Fernández, J., Nguyen, T. K. O., Gao, H., Christensen, T. A., Stojakovic, A., Trushin, S., Salisbury, J. L., Fuentealba, J., & Trushina, E. V. (2023) · Cells · doi:10.3390/cells12081111 · Cited by 29
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.